Burning Rock Announces Resignation and Appointment of Directors
28 Giugno 2023 - 10:05AM
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the
“Company” or “Burning Rock”), a company focused on the application
of next generation sequencing (NGS) technology in the field of
precision oncology, today announced the resignation of Dr. Shaokun
(Shannon) Chuai as a director from the board of directors of the
Company (the “Board”) and as the Company’s Chief Scientific
Officer, effective June 30, 2023. Dr. Shaokun (Shannon) Chuai will
continue to serve as a senior advisor to the Company. Dr. Zhihong
(Joe) Zhang, the Company’s Chief Technology Officer since March
2016, has been appointed as a new director of the Board, effective
June 30, 2023.
Mr. Yusheng Han, Burning Rock’s founder, chairman of the Board
and chief executive officer, commented, “We would like to take this
opportunity to thank Shannon for her high-impact service to Burning
Rock since 2014. Through her long tenure at Burning Rock, Shannon
has played an instrumental role in building Burning Rock's product
solutions, driving their adoption with leading physicians at
industry-leading forums, and building our science team. We wish her
the best in her new endeavors."
Dr. Chuai commented, "I have had an exhilarating, productive
journey at Burning Rock. I am very proud of the product portfolio
that we have developed over time with our team, spanning across
comprehensive genomic profiling for late-stage oncology patients,
minimal residual disease (MRD) for early-stage patients and
multi-cancer early detection. Each product category has reached
strong maturity with their respective product leaders and is well
on track in terms of commercial adoption. I am also proud of the
talent that we have developed internally at Burning Rock. In the
past seven months in my transition from Chief Operating Officer to
Chief Scientific Officer, our team leaders have demonstrated strong
leadership in driving the agenda forward and pushing the boundary
of our industry in new breakthroughs. So I think now is the right
time for me to move on, to do something new that I have never done
before, in a totally different industry outside of all my previous
career paths. I am proud of our collective achievements at Burning
Rock and am highly confident of Burning Rock's future going
forward.”
About Burning RockBurning Rock Biotech Limited
(NASDAQ: BNR and LSE: BNR), whose mission is to guard life via
science, focuses on the application of next generation sequencing
(NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage
cancer patients, and ii) cancer early detection, which has moved
beyond proof-of-concept R&D into the clinical validation
stage.For more information about Burning Rock, please visit:
ir.brbiotech.com.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements constitute
“forward-looking” statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in
the U.S. Private Securities Litigation Reform Act of 1995. These
forward- looking statements can be identified by terminology such
as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates,” “target,” “confident” and similar
statements. Burning Rock may also make written or oral
forward-looking statements in its periodic reports to the SEC, in
its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Statements that are not
historical facts, including statements about Burning Rock’s beliefs
and expectations, are forward-looking statements. Such statements
are based upon management’s current expectations and current market
and operating conditions, and relate to events that involve known
or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock’s
control. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
Grafico Azioni Burning Rock Biotech (LSE:BNR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Burning Rock Biotech (LSE:BNR)
Storico
Da Giu 2023 a Giu 2024